Search
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawnCetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Procaine benzylpenicillin
go.drugbank.com/drugs/DB09320ApprovedVet approvedProcaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. … This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required.
Mixtures: BENZAPEN 6.3.3 IM ENJ TOZ ICEREN FLAKON, 1 ADET, ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADETLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Omega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalFood and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids. … α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by
Mixtures: Prenatal Vitamin No 53 Iron Fum Folic Acid Docusate CA DHARanolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[L9194] SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.
Somatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigationalgrowth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug. … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and
Synonyms: .)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247Nandrolone phenpropionate
go.drugbank.com/drugs/DB00984ApprovedIllicitIt is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]